Logo XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. immune attack
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Immune Attack Articles & Analysis

25 news found

First-ever certified reference material to improve diagnosis of coeliac disease

First-ever certified reference material to improve diagnosis of coeliac disease

Coeliac disease is an autoimmune disorder occurring in genetically susceptible individuals when they eat food containing gluten. It triggers an immune response that mainly attacks the cells in the small intestine. ...

ByEuropean Commission, Joint Research Centre (JRC)


CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems   

CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems  

CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically modifying a patient's own immune cells to recognize and attack cancer cells more efficiently. By engineering these cells to express specific receptors on their surface, they acquire enhanced targeting capabilities against malignant ...

ByCD Formulation


First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

"Our AI platform basically mimics the human immune system using AI," said Ofran. "For this program, we chose the IL-2 pathway, which is well-studied and extensively explored. The antibody that is entering the clinic now was designed based on our understanding of the IL-2 pathway. We know IL-2 activates the immune system to attack the tumor, but ...

ByBiolojic Design, Ltd.


Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron

Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron

IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program Immune-Onc Therapeutics, Inc. ...

ByImmune-Onc Therapeutics, Inc.


Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform

About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

“We currently manage high-level BK viremia by reducing immunosuppressive therapy, which can help a patient’s immune system clear the virus, but this approach raises the risk that the immune system will attack and reject the graft. The potential for posoleucel to specifically restore immunity to BKV as an alternative ...

ByKalaris


Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

“Checkpoint inhibitors, such as anti-PD-1 and anti-PDL1 antibodies, have revolutionized cancer treatment by enabling the immune system to attack tumor cells,” said Luca Rastelli. “However, these antibodies have poor brain penetrance and shown limited efficacy in brain cancers. ...

ByJubilant Therapeutics Inc.


An Overview of Glioblastoma

An Overview of Glioblastoma

Immunotherapies are designed to restore the body’s own complex immune and defense mechanisms to recognize and destroy cancer cells. Checkpoint inhibitor therapy targets immune checkpoints, which are key regulators of the immune system that stimulate or inhibit its actions. Tumors can use these key regulators to protect themselves from ...

ByDiverse Biotech Inc


The Essential Guide to Food Allergies

The Essential Guide to Food Allergies

Usually a certain protein in the food is not welcomed by the patient’s body, generating a severe immune reaction. The body analyzes that protein as a foreign particle or antigen and attacks it with the help of immune cells. Allergic reactions are mediated by IgE type immune response. The IgE antibodies are formed on the ...

ByHYCOR Biomedical


Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company`s ImmCelz Product

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company`s ImmCelz Product

About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

“Clinical data previously collected by Cancer Research UK demonstrated peripheral immunogenicity in patients with NSCLC treated with VAC2, providing support to the underlying mechanism of using allogeneic dendritic cells to present tumor-associated antigens to the body’s immune system. Simultaneous with Cancer Research UK efforts to complete enrollment in the current ...

ByLineage Cell Therapeutics, Inc.


First patient dosed in SCIB1 Phase 2 clinical trial

First patient dosed in SCIB1 Phase 2 clinical trial

SCIB1 is the lead product from the Company’s ImmunoBody® immunotherapy platform, which uses the body’s immune system to identify, attack and destroy tumours. This is achieved by delivering a DNA plasmid using Ichor’s TriGrid® 2.0 electroporation delivery device to enhance the uptake and presentation of cancer antigens to harness high ...

ByScancell


Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz Supercharged Autologous Immunotherapy Platform

Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz Supercharged Autologous Immunotherapy Platform

ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" cells ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Cipla enters partnership to provide affordable oncology biosimilars to South Africa

Cipla enters partnership to provide affordable oncology biosimilars to South Africa

Cipla also recently launched a biosimilar for the treatment of immune-mediated inflammatory disease. According to the Cancer Alliance report CA03/2021, South Africa faces a crisis in terms of affordable access to medicines, particularly in the treatment of cancer. ...

BymAbxience


Update on Continued Research in Oncology

Update on Continued Research in Oncology

These are so-called prophylactic vaccines that teach the immune system to attack and get rid of hostile “invaders in the body” before disease can develop. During the last ten years, research has made great strides towards the application of such immunization strategies also in a more therapeutic fashion, so to treat already existing ...

ByAbera Bioscience AB


Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

VTP-600 is an immunotherapy, designed to stimulate the body’s immune system to attack cancer cells. It does this by delivering cancer-associated proteins — known as MAGE-A3 and NY-ESO-1 antigens — to antigen presenting cells (dendritic cells), causing the immune system to produce cytotoxic T cells which are able to target and ...

ByVaccitech plc


LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

” The GammabodyTM LAVA-051 is a bispecific antibody that recruits the immune system to attack CD1d-expressing cancer cells via the preferential activation of both Gamma Delta T cells and type 1 natural killer T (NKT) cells. ...

ByLAVA Therapeutics N.V.


AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products

AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products

Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T cells by the host immune system remains a key challenge to their broader development. Employing Caribou’s CRISPR genome editing platform to engineer CAR-T cells to withstand host ...

ByCaribou Biosciences, Inc.


Molecor brings water to the Bulgarian city of Pernik after months of severe drought

Molecor brings water to the Bulgarian city of Pernik after months of severe drought

Molecor has recently completed a major project: that of supplying the Bulgarian city of Pernik with drinking water. This city suffered extreme drought since November 2019. The absence of rain and the very low water level in the Studena dam, with 25 million cubic meters of capacity, threatened to leave a population of 100,000 people without potable water. In addition to the scarcity of flow from ...

ByMolecor Tecnologia S.L


T3 Pharmaceuticals wins highest endowed award for startup companies in Switzerland

T3 Pharmaceuticals wins highest endowed award for startup companies in Switzerland

Cancer immunotherapy is seen as a turning point in the fight against cancer: Unlike traditional therapies that attack the tumor directly, T3 Pharma’s immunotherapy stimulates the immune system to selectively recognize and attack tumor cells. ...

ByT3 Pharmaceuticals AG

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About XPRT Media

XPRT is a global industry marketplace and information resource. Online product catalogs, news, articles, events, publications & more.


  • FAQs
  • Company sitemap
  • Category sitemap
XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
Medical XPRT